{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"ASH Annual Meeting","description":"Peter Goodwin talks to key investigators Francesco Zaja (on rituximab  for ITP); Hannes Wandt (on how platelet transfusions may be able to be  withheld in certain patients receiving stem cell transplants for hematologic  cancers); and Michael Hallek and Tadeusz Robak (on improved  benefits for CLL patients with rituximab added to standard chemotherapy).  Offering perspective are Kenneth Kaushansky, Linda Burns, and  George Canellos.","author_name":"OT Broadcast News","author_url":"http:\/\/www.oncology-times.com","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/1109867\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/item\/1109867"}